ALK-Abello A/S
OTC:AKBLF

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
OTC:AKBLF
Watchlist
Price: 36.1 USD Market Closed
Market Cap: 7.6B USD

AKBLF's latest stock split occurred on Mar 29, 2022

The company executed a 20-for-1 stock split, meaning that for every share held, investors received 20 new shares.

Before the split, AKBLF traded at 18.125 per share. Afterward, the share price was about 18.125.

The adjusted shares began trading on Mar 29, 2022. This was the only stock split in AKBLF's history.

Last Splits:
Mar 29, 2022
20-for-1
Pre-Split Price
18.125 18.125
Post-Split Price
18.125
Before
After
Last Splits:
Mar 29, 2022
20-for-1

ALK-Abello A/S
Stock Splits History

AKBLF Stock Splits Timeline
Mar 29, 2022
Mar 29, 2022
Split 20-for-1
x20
Pre-Split Price
18.125 18.125
Post-Split Price
18.125
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

ALK-Abello A/S
Glance View

Market Cap
8B USD
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

AKBLF Intrinsic Value
31.67 USD
Overvaluation 12%
Intrinsic Value
Price
Back to Top